Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.70
(
0.00%
)
Bitcoin
78,204.34
(
-1.08%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

oc631

Send PM Follow Ignore
Followers 15
Posts 1749
Boards Moderated 0
Alias Born 08/12/2007

oc631

Re: jq1234 post# 163837

Thursday, 07/11/2013 5:12:39 PM

Thursday, July 11, 2013 5:12:39 PM

Post# of 257580

which is why this study without real comparator is called ph3b.





GILD has enough money to run countless studies and cover all the bases. One still has to wonder if this new Phase 3B study indicates a lack of confidence in their follow-up NS5A inhibitor GS-5816. If this drug is active in GT3 longer durations of Sofo/Riba will be an afterthought.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today